NASDAQ: SUPN

Price:
8.91
Change:
- 0.03
Day High:
8.99
Day Low:
8.80
Volume:
464,700
4:00 PM ET on Dec 19, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Press Releases

Search Press Releases

Keyword(s):

All Releases
View Summary Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R)
Dec 10, 2014
PDF 15.3 KB Add to Briefcase
View Summary Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
Dec 9, 2014
PDF 15.3 KB Add to Briefcase
View Summary Supernus Announces Issuance of Fifth U.S. Patent Protecting Trokendi XR(R)
Nov 24, 2014
PDF 20.3 KB Add to Briefcase
View Summary Supernus Sues Zydus for Infringement of Trokendi XR(R) Patents
Nov 21, 2014
PDF 19.8 KB Add to Briefcase
View Summary Supernus Announces Third Quarter 2014 Results
Nov 11, 2014
PDF 31.7 KB Add to Briefcase
View Summary Supernus Announces Issuance of Fourth U.S. Patent Protecting Trokendi XR(R)
Nov 7, 2014
PDF 17.3 KB Add to Briefcase
View Summary Supernus to Present at Two Investor Conferences
Nov 4, 2014
PDF 33.2 KB Add to Briefcase
View Summary Supernus to Host Third Quarter 2014 Earnings Conference Call
Oct 29, 2014
PDF 16.2 KB Add to Briefcase
View Summary Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
Oct 14, 2014
PDF 16.0 KB Add to Briefcase
View Summary Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents
Oct 2, 2014
PDF 16.9 KB Add to Briefcase
View Summary Supernus Provides Business Update
Sep 22, 2014
 
View Summary Supernus Announces Issuance of Fourth US Patent Protecting Oxtellar XR®
Sep 4, 2014
PDF 25.2 KB Add to Briefcase
View Summary Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
Aug 21, 2014
PDF 16.0 KB Add to Briefcase
View Summary Supernus to Attend FBR HealthCare Conference in September
Aug 19, 2014
PDF 14.6 KB Add to Briefcase
View Summary Supernus Receives FDA Fast Track Designation for SPN-810
Aug 14, 2014
PDF 17.5 KB Add to Briefcase
View Summary Supernus Announces Second Quarter 2014 Results
Aug 11, 2014
PDF 263.9 KB Add to Briefcase
View Summary Supernus to Host Second Quarter 2014 Earnings Conference Call
Jul 29, 2014
PDF 15.5 KB Add to Briefcase
View Summary Supernus to Receive $30 Million in Non-Dilutive Royalty Deal
Jul 8, 2014
PDF 83.9 KB Add to Briefcase
View Summary Supernus to Present at Jefferies Healthcare Conference in June
May 21, 2014
PDF 18.1 KB Add to Briefcase
View Summary Supernus Receives $2 Million Milestone for United Therapeutics' Launch of Orenitram(TM)
May 20, 2014
PDF 17.7 KB Add to Briefcase
Showing 1-20 of 85 Page: 1 2 3 4 5  Next 20
Add to Briefcase = add release to Briefcase

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, those statements regarding the company's future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. Forward-looking statements contain uncertainties, and may turn out to be materially different. Please see the company's risk factors enumerated in its filings with the Securities and Exchange Commission.